Frazier Life Sciences

Company Overview

Founded in 1991, Frazier Life Sciences is one of the longest-standing dedicated healthcare investment platforms in the U.S. The firm operates two distinct but complementary strategies: Frazier Healthcare Ventures (early-stage and company creation biopharma) and Frazier Healthcare Growth (commercial-stage healthcare and biopharma).

Frazier is known for deep scientific underwriting, long-duration ownership, and active board involvement. On the venture side, the firm frequently incubates companies internally, recruits founding management teams, and builds around differentiated biology or platforms with clear clinical endpoints. On the growth side, it targets capital-efficient businesses with established revenue, often partnering closely with management to scale operations or prepare for exit.

Company Focus

Frazier Life Sciences invests primarily in biopharma and healthcare, with clear segmentation by strategy:

• Venture platform:
  
  • Company creation and early-stage biopharma
  • Precision oncology, immunology, rare disease, and platform therapeutics
  • Strong emphasis on translational clarity and clinical path de-risking
• Growth platform:
  
  • Commercial-stage biopharma and healthcare services
  • Proven products, reimbursement visibility, and scalable operating models

The firm favors capital discipline, milestone-driven financing, and board-level engagement. Portfolios are relatively concentrated, and Frazier is comfortable leading rounds and maintaining ownership through multiple stages, including IPO and post-public support.

Portfolio Companies (Selections)

• Adaptive Biotechnologies — Immune-driven diagnostics; IPO 2019
• Seagen — Antibody-drug conjugates; acquired by Pfizer in 2023
• Lyell Immunopharma — T-cell reprogramming; IPO 2021
• Silverback Therapeutics — Precision biologics; IPO 2020
• Beigene — Global oncology platform; public
• Sana Biotechnology — Engineered cell therapies; IPO 2021
• Tizona Therapeutics — Acquired by Gilead
• Portola Pharmaceuticals — Acquired by Alexion (AstraZeneca)

Key Personals

Patrick Enright — Managing Partner (Venture)
Patrick Enright has been with Frazier for over two decades and is a central figure in shaping its venture strategy. He has led or co-led investments across oncology, immunology, and rare disease, and is known for hands-on company building from formation through clinical execution. His background combines deep operating judgment with long-cycle biotech investing discipline.

James Brush — Managing Partner (Growth Equity)
James Brush leads Frazier’s healthcare growth equity strategy, focusing on commercial-stage healthcare and biopharma companies. His work emphasizes operational scalability, durable revenue models, and partnership-driven growth, often supporting companies through late private stages and strategic exits.

‍